Advertisement

Tumor Biology

, Volume 35, Issue 4, pp 3899–3903 | Cite as

Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma

  • Ting Liu
  • Zeyuan Lei
  • ZhengYing Pan
  • Yu Chen
  • Xiang Li
  • TongChun Mao
  • Qian He
  • Dongli Fan
Research Article

Abstract

This study was designed to obtain a conclusive result about the relevance of p53 codon 72 polymorphism to the risk of cutaneous squamous cell carcinoma (SCC). We performed an updated meta-analysis of 3,792 subjects (1,349 cancer cases and 2,443 controls) to summarize the data available for p53 codon 72 polymorphism and SCC risk. The association was estimated by odds ratios (ORs) with 95 % confidence intervals (CIs). The meta-analysis showed no statistical significance for SCC risk associated with any of the genetic models of p53 codon 72 polymorphism. The analyses by ethnic subgroup also failed to produce significant associations. This study suggests that p53 codon 72 polymorphism does not appear to represent a significant susceptibility factor for SCC in Caucasians.

Keywords

p53 codon 72 Polymorphism SCC Risk Meta-analysis 

Notes

Conflicts of interest

None.

References

  1. 1.
    Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30(5 Pt 1):774–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Mueller CS, Reichrath J. Histology of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008;624:215–26.PubMedCrossRefGoogle Scholar
  3. 3.
    Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146 Suppl 61:1–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med. 1992;327(23):1649–62.PubMedCrossRefGoogle Scholar
  5. 5.
    Rees J. Genetic alterations in non-melanoma skin cancer. J Invest Dermatol. 1994;103(6):747–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Tilli CM et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol. 2005;152(6):1108–24.PubMedCrossRefGoogle Scholar
  7. 7.
    Albert MR, Weinstock MA. Keratinocyte carcinoma. CA Cancer J Clin. 2003;53(5):292–302.PubMedCrossRefGoogle Scholar
  8. 8.
    Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327(7418):794–8.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Hollstein M et al. p53 mutations in human cancers. Science. 1991;253(5015):49–53.PubMedCrossRefGoogle Scholar
  10. 10.
    Thomas M et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19(2):1092–100.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Dumont P et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.PubMedCrossRefGoogle Scholar
  12. 12.
    Henner WD et al. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate. 2001;49(4):263–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Wu X et al. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94(9):681–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Fan R et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9(10):1037–42.PubMedGoogle Scholar
  15. 15.
    Soulitzis N et al. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002;179(2):175–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Shen H et al. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002;183(2):123–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Helland A et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396(6711):530–1. author reply 532.PubMedCrossRefGoogle Scholar
  18. 18.
    Andersson S et al. The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas. Br J Cancer. 2001;85(8):1153–6.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Dokianakis DN et al. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5(4):405–9.PubMedGoogle Scholar
  20. 20.
    Marshall SE et al. p53 codon 72 polymorphism and susceptibility to skin cancer after renal transplantation. Transplantation. 2000;69(5):994–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Bastiaens MT et al. Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? Mol Carcinog. 2001;30(1):56–61.PubMedCrossRefGoogle Scholar
  22. 22.
    Cairey-Remonnay S et al. TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status. J Invest Dermatol. 2002;118(6):1026–31.PubMedCrossRefGoogle Scholar
  23. 23.
    McGregor JM et al. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol. 2002;119(1):84–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Gustafsson AC et al. The role of p53 codon 72 and human papilloma virus status of cutaneous squamous cell carcinoma in the Swedish population. Acta Derm Venereol. 2004;84(6):439–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Han J et al. The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinog. 2006;45(9):694–700.PubMedCrossRefGoogle Scholar
  26. 26.
    Bendesky A et al. p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. Mutat Res. 2007;619(1–2):38–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Almquist LM et al. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Carcinogenesis. 2011;32(3):327–30.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Loeb KR et al. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas. PLoS One. 2012;7(4):e34422.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMedGoogle Scholar
  31. 31.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRefGoogle Scholar
  32. 32.
    Egger M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Jiang DK et al. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol. 2011;131(1):220–8.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Ting Liu
    • 1
  • Zeyuan Lei
    • 1
  • ZhengYing Pan
    • 1
  • Yu Chen
    • 1
  • Xiang Li
    • 1
  • TongChun Mao
    • 1
  • Qian He
    • 1
  • Dongli Fan
    • 1
  1. 1.Department of Plastic and Cosmetic Surgery, XinQiao HospitalThe Third Military Medical UniversityChongQingChina

Personalised recommendations